Elevated Thrombotic Activity after Myocardial Infarction: A 2-Year Follow-Up StudyMartínez-Sales V.a · Vila V.a · Réganon E.a · Goberna M.A.a · Ferrando F.b · Palencia M.A.c · Aznar J.b
aResearch Center, bDepartment of Clinic Pathology, and cDivision of Cardiology, La Fe University Hospital, Valencia, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
This study examines the evolution of the thrombotic activity in patients with myocardial infarction (MI) treated with aspirin (200 mg/day) for 2 years after MI. Plasma samples of 10 patients were collected at 7, 30, 60, 90, 120, 150, 180, 360 and 720 days. In all the samples we measured fibrinogen (Fg), high molecular weight Fg (HMW-Fg), fibrinopeptide A (FPA), prothrombin fragment 1+2 (F1+2), β-thromboglobulin (β-TG), von Willebrand factor (vWF), tissue factor (TF) and TF pathway inhibitor (TFPI). The plasma Fg, HMW-Fg, FPA, F1+2, β-TG and vWF levels were significantly elevated in the patients at the beginning of the study as compared to the normal group. The 95% confidence intervals were Fg 277–333 mg/dl, HMW-Fg 200–244 mg/dl, FPA 5.3–16.5 ng/ml, F1+2 1.4–1.8 nmol/l, β-TG 110–118 IU/ml and vWF 139–195%. At thirty days Fg and HMW-Fg returned to normal levels, whereas the increase in FPA and F1+2 levels persisted throughout the study. At 120 and 150 days, respectively, β-TG and vWF returned to normal levels. The increase in thrombin generation and activity pointed to a persistent hypercoagulable state 2 years after MI. Plasma levels of TF and TFPI showed no statistically significant variations with respect to the normal values over the 2-year period studied. In conclusion, these results suggest a persistent generation and activity of thrombin and cellular activation in these patients after MI.
- Vila V, Réganon E, Aznar J, Lacueva V, Ruano M, Laiz B: Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase. Thromb Res 1990;57:783–794.
- Réganon E, Vila V, Aznar J, Lacueva V, Martínez V, Ruano M: Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase. Increase in the rate of fibrinopeptide release. Thromb Haemost 1993;70:978–983.
- Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR: Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994;24:1445–1452.
- Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci M, Rosenberg RD: Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995;25:203–209.
- Salvioni A, Marenzi G, Lauri G, Giraldi F, Perego GB, Grazi S, Guazzi MD: β-Thromboglobulin plasma levels in the first week after myocardial infarction: Influence of thrombolytic therapy. Am Heart J 1994;128:472–476.
- Andreotti F, Roncaglioni MC, Hackett DR, Khan MI, Regan T, Haider AW, Davies GJ, Kluft C, Maseri A: Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990;16:1553–1560.
- Magulis T, Davis M, Maor N, Soff GA, Grenadier E, Palant A, Aghai E: The von Willebrand factor in myocardial infarction and unstable angina: A kinetic study. Thromb Haemost 1986;55:366–368.
- Lorena M, Perolini S, Casazza S, Milani M, Cimminiello C: Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. Thromb Res 1997;87:397–403.
- Suefuji H, Ogawa H, Yasue H, Kaikita K, Souejima H, Motoyama T, Mizuno Y, et al: Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997;134:253–259.
- Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG: Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998;79:495–499.
- Granger ChB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, et al: Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-I trial. J Am Coll Cardiol 1998;31:497–505.
Low EJ, Hill HB, Searly RL: Simple method for determination of normal plasma fibrinogen levels. Am J Clin Pathol 1967;47:538–548.
- Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T. Nature 1970;227:680–686.
- Towbin H, Stachelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350–4354.
- Kockum C, Frebelius S: Rapid radioimmunoassay of human fibrinopeptide A – Removal of cross-reacting fibrinogen with bentonite. Thromb Res 1980;19:589–598.
- Rapold HJ, de Bono D, Arnold AER, Arnout J, De Cock F, Coller D, Vestratete M, for the European Cooperative Study Group: Plasma fibrinopeptide A levels in patients with acute myocardial infraction treated with alteplase: Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992;85:928–934.
- Merlini PA, Bauer KA, Oltrona L, Ardissini D, Cattaneo M, Belli C, Mannucci PM, Rosemberg RD: Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61–68.
- Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, Randall A, et al: Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial). Am J Cardiol 1996;78:142–147.
- Bauer KA, Rosemberg RD: The patophysiology of the prethrombotic state in humans: Insight gained from studies using markers of hemostatic system activation. Blood 1987;70:343–350.
- Stel HV, Sakariassen KS, De Groot PG, van Mourik JA, Sixama JJ: von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985;65:85–90.
- Tousoulis D, Davies G, Tentolouris C, Bosinakou E, Toutouzas P: Relation of von Willebrand factor to occurrence of Q waves and thrombolytic treatment in acute myocardial infarction. Am J Cardiol 1998;81:497–500.
- Uren NG, Crake T, Lefroy DC, DeSilva R, Davis GJ, Maseri A: Reduced coronary vasodilatator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1997;331:222–227.
Davis MJ: A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(suppl II):II-38–II-46.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.